hola

Lorem ipsum dolor sit amet ¹, consectetur adipiscing elit. Quisque erat eros, cursus² sit amet libero id, accumsan ornare lorem. Curabitur purus orci ³, luctus non leo non, varius accumsan lectus. Phasellus ut euismod libero, sit amet semper mi. Aliquam malesuada quis lectus egestas ultricies. Aenean arcu neque, finibus vitae augue ut, finibus mollis sem. Aliquam ac erat lacus. Donec ut aliquam sem. Curabitur consequat, neque id auctor ornare, nunc mauris aliquam nulla, finibus ullamcorper purus nisi sed lectus. Quisque maximus pulvinar mi, in tincidunt eros pulvinar varius. Nunc luctus tellus sed enim fringilla, quis sollicitudin enim vehicula. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sed diam consectetur metus bibendum mattis at sed sem. Sed eget quam id lorem aliquet egestas. Vivamus ullamcorper felis ut tortor ultricies ultricies. Nunc tortor dui, tempor sit amet volutpat eu, ornare id mi. Aliquam ut massa consectetur, finibus eros vitae, eleifend elit.

Duis id dictum purus.⁴ Quisque vel purus ut ante placerat faucibus ut eget urna. Donec non rutrum eros, eget porta mauris. Nulla scelerisque congue lacus, nec dapibus dolor. Praesent lobortis justo metus, vitae congue mi fringilla at. Quisque sit amet enim non neque tristique accumsan non non nulla. Pellentesque consequat erat vitae nibh pretium, at consectetur massa fermentum. Donec dapibus fermentum magna eu placerat. Sed mattis lorem hendrerit lectus ultricies, non ullamcorper risus ultrices. Vivamus commodo lorem dolor, a tristique orci fringilla id. Pellentesque quam nunc, ullamcorper eget cursus gravida, tristique eget odio. Suspendisse ut sodales purus.

Imagine a future in which treatment goals we once thought unattainable could be reached. GSK, along with global specialists and patient organisations, is aiming to achieve just that by applying years of expertise in respiratory disease, and a deep understanding of the immune system, to develop solutions that can help some people with severe asthma achieve clinical remission.

Asthma affects more than 300 million people worldwide and varies in terms of severity. At least 10% of people with asthma have severe asthma, and of those, 80% have elevated levels of a type of white blood cell called eosinophils, which cause lung inflammation and severe eosinophilic asthma.

People with severe asthma can face many years before they receive a specific diagnosis of their type of asthma, wasting time, sometimes year, of frustrating trial and error approaches to treatment options. Alongside the ongoing damage caused to a patient’s lungs due to avoidable exacerbations, this can also take a toll on their mental health, work and social life.

external link

Broken link

Click here